Taysha Gene Therapies to End Development of TSHA-120 After FDA Feedback
September 19 2023 - 4:52PM
Dow Jones News
By Ben Glickman
Taysha Gene Therapies will discontinue development of its
TSHA-120 program to treat giant axonal neuropathy after receiving
feedback from the U.S. Food and Drug Administration.
The Dallas-based gene-therapy developer said that it had
received Type C meeting feedback from the FDA. Chief Executive Sean
Nolan said that the feedback pointed out "challenges related to the
feasibility of the study designs" to support approval by the
FDA.
The company will pursue external strategic options for TSHA-120,
which is meant to extend Taysha's cash runway into the fourth
quarter of 2025.
Taysha said that Astellas Gene Therapy had decided not to
exercise its exclusive license option under a prior agreement
between the two companies.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 19, 2023 16:37 ET (20:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2024 to May 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From May 2023 to May 2024
